Analysts Anticipate Genocea Biosciences Inc (NASDAQ:GNCA) to Announce -$0.45 Earnings Per Share

Wall Street analysts forecast that Genocea Biosciences Inc (NASDAQ:GNCA) will announce earnings of ($0.45) per share for the current quarter, Zacks reports. Zero analysts have made estimates for Genocea Biosciences’ earnings, with the lowest EPS estimate coming in at ($0.56) and the highest estimate coming in at ($0.39). Genocea Biosciences posted earnings of ($0.72) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 37.5%. The company is scheduled to announce its next quarterly earnings results on Thursday, November 7th.

According to Zacks, analysts expect that Genocea Biosciences will report full year earnings of ($2.36) per share for the current year, with EPS estimates ranging from ($2.77) to ($2.13). For the next financial year, analysts forecast that the company will report earnings of ($1.64) per share, with EPS estimates ranging from ($1.87) to ($1.21). Zacks’ EPS averages are an average based on a survey of research analysts that that provide coverage for Genocea Biosciences.

Genocea Biosciences (NASDAQ:GNCA) last released its quarterly earnings data on Thursday, July 25th. The biotechnology company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.02).

Several brokerages have recently weighed in on GNCA. Stifel Nicolaus began coverage on shares of Genocea Biosciences in a research note on Monday, July 8th. They issued a “buy” rating for the company. ValuEngine upgraded shares of Genocea Biosciences from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Zacks Investment Research upgraded shares of Genocea Biosciences from a “hold” rating to a “buy” rating and set a $4.50 target price for the company in a research note on Wednesday, July 3rd. Finally, HC Wainwright restated a “buy” rating and issued a $32.00 target price (down from $42.00) on shares of Genocea Biosciences in a research note on Thursday, July 25th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Genocea Biosciences currently has a consensus rating of “Buy” and an average price target of $18.25.

In other Genocea Biosciences news, major shareholder Peter W. Sonsini bought 2,857,142 shares of the company’s stock in a transaction on Monday, June 24th. The shares were bought at an average cost of $3.50 per share, with a total value of $9,999,997.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 2.33% of the stock is currently owned by corporate insiders.

Several large investors have recently modified their holdings of GNCA. Morgan Stanley acquired a new stake in shares of Genocea Biosciences during the second quarter worth $26,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Genocea Biosciences in the 2nd quarter worth about $40,000. Wedbush Securities Inc. acquired a new stake in shares of Genocea Biosciences in the 2nd quarter worth about $43,000. Citadel Advisors LLC acquired a new stake in shares of Genocea Biosciences in the 2nd quarter worth about $68,000. Finally, D. E. Shaw & Co. Inc. acquired a new stake in shares of Genocea Biosciences in the 2nd quarter worth about $84,000.

Shares of GNCA stock traded down $0.11 on Wednesday, hitting $3.01. The stock had a trading volume of 364 shares, compared to its average volume of 170,406. The firm has a market capitalization of $81.58 million, a price-to-earnings ratio of -0.82 and a beta of 2.40. The stock’s 50 day moving average is $3.53 and its 200-day moving average is $2.18. The company has a debt-to-equity ratio of 0.45, a quick ratio of 5.96 and a current ratio of 5.96. Genocea Biosciences has a 52-week low of $2.24 and a 52-week high of $11.28.

About Genocea Biosciences

Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses.

Featured Story: What are different types of coverage ratios?

Get a free copy of the Zacks research report on Genocea Biosciences (GNCA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Genocea Biosciences (NASDAQ:GNCA)

Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.